MedTrace Logo

Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic

NCT04974164 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1400

Last updated 2022-08-23

No results posted yet for this study

Summary

This study is a multisite ,grouped test-negative case-control , phase Ⅳ clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The purpose of this study is to estimate the protective effectiveness of complete vaccination (measured ≥14 days after the second dose) of CoronaVac against symptomatic SARS-COV-2 infections ,COVID-19 hospitalizations and severe cases.

Conditions

Interventions

BIOLOGICAL

Inactivated COVID-19 Vaccine

Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen

Sponsors & Collaborators

  • Sinovac Research and Development Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Eddy Perez-Then, Doctor · Ministry of Health

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-17
Primary Completion
2021-10-17
Completion
2021-12-13

Countries

  • Dominican Republic

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04974164 on ClinicalTrials.gov